Sight Sciences Wins Infringement Lawsuit Against Alcon

Court preserves jury's finding of willful infringement and awards over $34 million in damages to Sight Sciences

Mar. 30, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

A sleek, metallic medical device component floating against a plain white background, representing the innovative glaucoma treatment technology at the heart of the patent dispute between Sight Sciences and Alcon.An award-winning medical device at the center of a high-stakes patent battle symbolizes the innovative spirit driving advancements in glaucoma care.Menlo Park Today

Sight Sciences, Inc. announced that the U.S. District Court for the District of Delaware issued an order on post-trial motions in Sight Sciences' patent infringement case against Alcon Inc. and its affiliates. The court preserved the jury's verdict that Alcon willfully infringed three of Sight Sciences' patents related to the Hydrus Microstent device and awarded Sight Sciences over $34 million in past damages, plus an ongoing 10% royalty on Hydrus sales through November 2028.

Why it matters

This ruling is a significant victory for Sight Sciences, as it validates the strength of the company's intellectual property portfolio in the interventional glaucoma space. The ongoing royalties will provide Sight Sciences with a steady revenue stream to continue investing in its pipeline of innovative eye care technologies.

The details

The court's order did not disturb the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents. The $34 million in past damages includes $5.5 million in lost profits and $28.5 million in royalty damages for Hydrus sales from its commercial launch through the jury verdict, plus pre-judgment and post-judgment interest. Sight Sciences will also receive an ongoing 10% royalty on Hydrus revenue through November 10, 2028, the expiration date of Sight Sciences' last asserted patent.

  • The jury's verdict was reached in 2026.
  • The court's order on post-trial motions was entered on March 27, 2026.
  • The final judgment is expected to be entered by the court in the coming months.

The players

Sight Sciences, Inc.

An eyecare technology company focused on developing and commercializing innovative, interventional solutions for eye diseases like glaucoma.

Alcon Inc.

A global medical device company that manufactures and sells the Hydrus Microstent, which was found to infringe Sight Sciences' patents.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased with the results of the ruling and the recognition of our strong intellectual property portfolio in interventional glaucoma. Since 2006, Sight Sciences has been committed to elevating the standard of glaucoma care by pioneering and developing the field of circumferential microinvasive glaucoma surgery.”

— Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences

What’s next

The final judgment is subject to appeal by Alcon, and may also be affected by ex parte reexamination proceedings filed by Alcon with the U.S. Patent and Trademark Office.

The takeaway

This court victory solidifies Sight Sciences' position as a leader in the interventional glaucoma space and allows the company to continue investing in its pipeline of innovative eye care technologies to further elevate the standard of care for glaucoma patients.